Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Travere Therapeutics (TVTX) Liabilities from Discontinued Operations (2022)

Travere Therapeutics' Liabilities from Discontinued Operations history spans 1 years, with the latest figure at 7000000.0 for Q4 2022.

For Q4 2022, Liabilities from Discontinued Operations changed N/A year-over-year to 7000000.0; the TTM value through Dec 2022 reached 7000000.0, changed N/A, while the annual FY2022 figure was 7000000.0, N/A changed from the prior year.
Liabilities from Discontinued Operations reached 7000000.0 in Q4 2022 per TVTX's latest filing.
In the past five years, Liabilities from Discontinued Operations ranged from a high of 7000000.0 in Q4 2022 to a low of 7000000.0 in Q4 2022.